- Mallinckrodt (NYSE:MNK) initiates a retrospective chart review study to collect real-world data on the use of INOmax (nitric oxide) gas for inhalation therapy in COVID-19 patients with respiratory complications.
- The company will work with Pharmerit to collect data from ~200 hospitalized adult patients who received INOmax therapy for at least 24 hours between January 1, 2020 and July 31, 2020. Results will be reviewed from admission to 30 days after discharge.
- https://seekingalpha.com/news/3634234-mallinckrodt-launches-retrospective-study-on-use-of-nitric-oxide-in-covidminus-19
Tuesday, November 10, 2020
Mallinckrodt in retrospective study on use of nitric oxide in COVID-19
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.